Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• High levels of polo-like kinase 1 (PLK1) are observed in hepatocellular carcinoma (HCC).
• Mechanisms regulating PLK1 expression in HCC remain unclear.
• PLK1 inhibitors are under clinical investigation for HCC treatment.

Purpose of the Study:

• To investigate the regulatory role of let-7b in PLK1 expression within HCC.
• To elucidate the impact of let-7b on HCC cell proliferation, apoptosis, and tumor growth.
• To identify downstream targets and pathways affected by let-7b-mediated PLK1 regulation.

Main Methods:

• Luciferase reporter assays in HEK-293T cells to assess PLK1 regulation by let-7b.
• Quantitative analysis of let-7b and PLK1 expression in HCC cell lines and patient tissues.
• In vitro studies on HCC cell proliferation and apoptosis following let-7b overexpression.
• In vivo studies using a mouse xenograft model of HCC.
• Western blot analysis to evaluate protein phosphorylation and expression levels.

Main Results:

• let-7b overexpression inhibited PLK1 activity and expression in HCC cells.
• A negative correlation was found between let-7b and PLK1 levels in HCC tissues.
• let-7b suppressed HCC cell proliferation and induced apoptosis, effects partially reversed by increased PLK1.
• let-7b reduced phosphorylation of PLK1 targets (CDC25C, Survivin) and expression of key proteins (CDC2, β-catenin, TCF-4).
• let-7b inhibited HCC tumor development and growth in vivo by decreasing PLK1 and Survivin.

Conclusions:

• let-7b directly targets PLK1 to inhibit HCC progression.
• let-7b exerts its tumor-suppressive effects by attenuating PLK1-mediated Survivin phosphorylation.
• let-7b represents a potential therapeutic target for HCC treatment.